MNMD Stock Forecast: MindMed tumbles in a rocky start to the week of trading
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NASDAQ:MNMD fell by 20.99% during Tuesday’s trading session.
- MindMed might have a bright future but there is risk involved.
- More pain for meme stocks as AMC, GME, and BBBY extend their slide.
NASDAQ:MNMD hit a brick wall on Tuesday as the psychedelic biotech company saw its stock price fall off a cliff coming out of the Labor Day long weekend. Shares of MNMD tumbled by 20.99% and closed the trading session at a price of $9.07. This would make its pre-split adjusted price at just $0.60 per share. Stocks extended their declines as all three major indices closed the day in the red. Stronger than expected ISM data from August weighed on investors ahead of the September FOMC meeting on interest rates. Overall, the Dow Jones fell by 173 basis points, the S&P 500 slipped by 0.41%, and the NASDAQ dropped by 0.74% during the session.
Stay up to speed with hot stocks' news!
The reverse stock split certainly leaves a bad taste in the mouths of investors. Just ask those that are invested in cannabis company Sundia (NASDAQ:SNDL). But MindMed does have some promising catalysts including five projects which are in Phase 2 of their clinical trials which means there are plenty of potential treatments coming down the pipeline. It also has a decent cash balance which can allow it to continue with these trials without making much in terms of revenues.
MNMD stock price
MindMed wasn’t the only meme stock declining on Tuesday. Shares of AMC (NYSE:AMC) were down by 7.77%, GameStop (NYSE:GME) by 8.11%, and Bed Bath and Beyond (NASDAQ:BBBY) a further 18.42%. It’s been an ugly couple of weeks for meme stocks following the BBBY short squeeze, and it doesn’t seem like there is any relief on the horizon for meme stock traders.
Like this article? Help us with some feedback by answering this survey:
- NASDAQ:MNMD fell by 20.99% during Tuesday’s trading session.
- MindMed might have a bright future but there is risk involved.
- More pain for meme stocks as AMC, GME, and BBBY extend their slide.
NASDAQ:MNMD hit a brick wall on Tuesday as the psychedelic biotech company saw its stock price fall off a cliff coming out of the Labor Day long weekend. Shares of MNMD tumbled by 20.99% and closed the trading session at a price of $9.07. This would make its pre-split adjusted price at just $0.60 per share. Stocks extended their declines as all three major indices closed the day in the red. Stronger than expected ISM data from August weighed on investors ahead of the September FOMC meeting on interest rates. Overall, the Dow Jones fell by 173 basis points, the S&P 500 slipped by 0.41%, and the NASDAQ dropped by 0.74% during the session.
Stay up to speed with hot stocks' news!
The reverse stock split certainly leaves a bad taste in the mouths of investors. Just ask those that are invested in cannabis company Sundia (NASDAQ:SNDL). But MindMed does have some promising catalysts including five projects which are in Phase 2 of their clinical trials which means there are plenty of potential treatments coming down the pipeline. It also has a decent cash balance which can allow it to continue with these trials without making much in terms of revenues.
MNMD stock price
MindMed wasn’t the only meme stock declining on Tuesday. Shares of AMC (NYSE:AMC) were down by 7.77%, GameStop (NYSE:GME) by 8.11%, and Bed Bath and Beyond (NASDAQ:BBBY) a further 18.42%. It’s been an ugly couple of weeks for meme stocks following the BBBY short squeeze, and it doesn’t seem like there is any relief on the horizon for meme stock traders.
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.